U.S. Patent No.
6,627,196 (Dosages for Treatment with Anti-ErbB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Samsung Bioepis, Co., Ltd.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-3, 5, 7, 9-11, 17-33

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y; Joined with IPR2017-00804

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1174

IPR Status
Joined with IPR2017-00804; Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed

U.S. Patent No.
7,371,379 (Dosages for Treatment with Anti-ErbB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Samsung Bioepis, Co., Ltd.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-3, 5, 7, 9-11, 16-28, 30-40

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y; Joined with IPR2017-00805

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1173

IPR Status
Joined with IPR2017-00805; Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed

U.S. Patent No.
7,892,549 (Treatment with Anti-ErbB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Samsung Bioepis, Co., Ltd.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-17

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y; Joined with IPR2017-00737

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1265

IPR Status
Joined with IPR2017-00737; Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Terminated as to Hospira, Motion for Samsung Bioepis to Withdraw as a Party Granted, Ongoing with USPTO Director as Intervenor

U.S. Patent No.
6,407,213 (Method for Making Humanized Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Samsung Bioepis, Co., Ltd.

§ 102 Challenge
Y: Claims 1, 2, 4, 25, 29, 62-64, 66, 67, 71, 72, 75, 76, 80, 81

Claim Types Challenged Under § 102
Composition of Matter

§ 102 Challenge Instituted
Y; Joined with IPR2017-01488

§ 103 challenge
Y: Claims 1, 2, 4, 12, 25, 29-31, 33, 42, 60, 62-67, 69, 71-81

Claim Types Challenged Under § 103
Composition of Matter

§ 103 Challenge Instituted
Y; Joined with IPR2017-01488

Final Written Decision Issued
Y

IPR Status
Joined with IPR2017-01488; Final Written Decision (Some Instituted Claims Found Unpatentable)

U.S. Patent No.
6,407,213 (Method for Making Humanized Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Samsung Bioepis, Co., Ltd.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1, 2, 4, 12, 25, 29-31, 33, 42, 60, 62-67, 69, 71-81

Claim Types Challenged Under § 103
Composition of Matter

§ 103 Challenge Instituted
Y; Joined with IPR2017-01489

Final Written Decision Issued
Y

IPR Status
Joined with IPR2017-01489; Final Written Decision (Some Instituted Claims Unpatentable)

U.S. Patent No.
7,846,441 (Treatment with Anti-ERBB2 Antibodies)

Patent Owner
Genentech, Inc.

Petitioner(s)
Samsung Bioepis, Co., Ltd.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted